Merck and Moderna report that their cancervaccine candidate showed positive results in their late-stage trial in preventing a recurrence of melanoma, including in high-risk patients.
Merck and Moderna reports that their cancer vaccine candidate showed positive results in their late-stage trial in preventing a recurrence of melanoma, including in high-risk patients.
Merck and Moderna report that their cancer vaccine candidate showed positive results in their late-stage trial in preventing a recurrence of melanoma, including in high-risk patients.